<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04820894</url>
  </required_header>
  <id_info>
    <org_study_id>19322</org_study_id>
    <secondary_id>NCI-2021-01818</secondary_id>
    <secondary_id>19322</secondary_id>
    <secondary_id>P30CA033572</secondary_id>
    <nct_id>NCT04820894</nct_id>
  </id_info>
  <brief_title>Perception of Cure Among Patients With Metastatic Cancer</brief_title>
  <official_title>The Perception of Cure Among Patients With Metastatic Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>City of Hope Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>City of Hope Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study collects information about perception of cure among patients with cancer that has&#xD;
      spread to other places in the body (metastatic). This study aims to determine patients'&#xD;
      perception (knowledge) before starting immunotherapy and if differences exist in&#xD;
      understanding of treatment to stimulate or restore the ability of the body's immune (defense)&#xD;
      system to fight infection and disease (immunotherapy) based on social and economic factors or&#xD;
      on race/ethnicity.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVE:&#xD;
&#xD;
      I. To assess the proportion of patients with metastatic cancer who anticipate cure before&#xD;
      starting immunotherapy.&#xD;
&#xD;
      SECONDARY OBJECTIVES:&#xD;
&#xD;
      I. To determine if expectations of cure are associated with quality of life and distress.&#xD;
&#xD;
      II. To determine if patients' perceptions differ by gender, age, and ethnicity.&#xD;
&#xD;
      OUTLINE:&#xD;
&#xD;
      Patients complete surveys over 30 minutes about sociodemographic information and perception&#xD;
      of immunotherapy, over 10 minutes about expectations of cure, over 10 minutes about anxiety,&#xD;
      over 10 minutes about depression, and over 30 minutes about physical well-being. Patients'&#xD;
      medical records are reviewed.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">October 30, 2021</start_date>
  <completion_date type="Anticipated">March 30, 2023</completion_date>
  <primary_completion_date type="Anticipated">March 30, 2023</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of patients</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>Will assess the percentage of patients who anticipate cure before starting immunotherapy, scoring a '1' on the Perception of cure tool, and anticipate &gt;75% chance for a cure.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Patient Reported Outcomes Measurement Information System (PROMIS)</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>Descriptive analyses (e.g. frequency statistics) will be used to characterize the sample and to look at the association between Patient Reported Outcomes Measurement Information System (PROMIS) tool score with perception of cure score.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Functional Assessment of Cancer Therapy-General (FACT-G)</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>Descriptive analyses (e.g. frequency statistics) will be used to characterize the sample and to look at the association between Functional Assessment of Cancer Therapy-General (FACT-G) overall score with perception of cure score.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Perceptions of cure</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>Chi-square analyses will be used to examine perceptions of cure by sociodemographic characteristics:&#xD;
gender (male and female), age (&lt; 60 and &gt; 60), and ethnicity (white non-Hispanic, Hispanic, and other).</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Hematopoietic and Lymphoid Cell Neoplasm</condition>
  <condition>Metastatic Malignant Solid Neoplasm</condition>
  <arm_group>
    <arm_group_label>Observational (survey, medical records review)</arm_group_label>
    <description>Patients complete surveys over 30 minutes about sociodemographic information and perception of immunotherapy, over 10 minutes about expectations of cure, over 10 minutes about anxiety, over 10 minutes about depression, and over 30 minutes about physical well-being. Patients' medical records are reviewed.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Electronic Medical Record</intervention_name>
    <description>Medical records are reviewed</description>
    <arm_group_label>Observational (survey, medical records review)</arm_group_label>
    <other_name>Computer Based Patient Record</other_name>
    <other_name>EMR</other_name>
    <other_name>EMR (electronic medical record)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Survey Administration</intervention_name>
    <description>Complete surveys</description>
    <arm_group_label>Observational (survey, medical records review)</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with metastatic cancer&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Eligibility Criteria:&#xD;
&#xD;
          1. Patients must be aged 18 and over&#xD;
&#xD;
          2. Patients sufficiently fluent in English&#xD;
&#xD;
          3. Patients must have a cytologically or pathologically verified diagnosis of cancer&#xD;
&#xD;
          4. Patients must have measurable metastatic disease&#xD;
&#xD;
          5. Patients must be initiating immunotherapy&#xD;
&#xD;
          6. Patients must be undergoing evaluation and treatment at City of Hope Cancer Center&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sumanta K Pal</last_name>
    <role>Principal Investigator</role>
    <affiliation>City of Hope Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>City of Hope Medical Center</name>
      <address>
        <city>Duarte</city>
        <state>California</state>
        <zip>91010</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sumanta K. Pal</last_name>
      <phone>626-256-4673</phone>
      <email>spal@coh.org</email>
    </contact>
    <investigator>
      <last_name>Sumanta K. Pal</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>March 25, 2021</study_first_submitted>
  <study_first_submitted_qc>March 25, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 29, 2021</study_first_posted>
  <last_update_submitted>August 10, 2021</last_update_submitted>
  <last_update_submitted_qc>August 10, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 12, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
    <mesh_term>Neoplasm Metastasis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

